Table 2.

EBR/GZR‐related adverse events

Adverse events (AE) (n)(%)	Overall (n = 149)	Cirrhosis (n = 79)	Noncirrhosis (n = 70)	P value
≧1 AEs	44 (30.2)	26 (32.9)	18 (25.7)	.3365
Total bilirubin elevation	11 (7.4)	10 (12.7)	1 (1.4)	.0089
Insomnia	6 (4.0)	3 (3.8)	3 (4.3)	.8797
Dizziness	6 (4.0)	4 (5.1)	2 (2.9)	.4942
Fatigue	6 (4.0)	2 (2.5)	4 (5.7)	.3240
ALT elevation	5 (3.4)	3 (3.8)	2 (2.9)	.7504
Headache	4 (2.7)	1 (1.3)	3 (4.3)	.2550
Pruritus	3 (2.0)	2 (2.5)	1 (1.4)	.6323
Skin reaction	1 (0.7)	1 (1.3)	0 (0)	.3449
Nausea	1 (0.7)	0 (0)	1 (1.4)	.2865
Dry mouth	1 (0.7)	0 (0)	1 (1.4)	.2865
Management of AE, n (%)
Observation	32 (21.5)	18 (22.8)	14 (20.0)	.6795
Medication	9 (6.0)	6 (7.6)	3 (4.3)	.3974
Drug discontinuation	3 (2.0)	2 (2.5)	1 (1.4)	.6323

Note: Total bilirubin normal range ≦ 1.3 mg/dL; ALT normal range ≦ 36 U/L.

Abbreviations: ALT, alanine aminotransferase; EBR/GZR, elbasvir/grazoprevir.